| Name | Chlorpheniramine maleate |
| Description | Chlorpheniramine maleate (NCI-C55265) is a histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. |
| Cell Research | Cells are exposed to various concentrations of Chlorpheniramine for 48 hours. Cells are washed, detached, and counted with a Coulter counter for the determination of cell growth.(Only for Reference) |
| Kinase Assay | H1-Antihistaminic Activity: The segments (1 cm) of isolated ileum from guinea pigs are suspended in an organ bath containing Tyrode solution (ventilation, 32 °C). The contractile responses to histamine (0.54 μM) are measured with an isotonic transducer. A set concentration of Chlorpheniramine is added in the organ bath 5 minutes before the addition of histamine. IC50 value of Chlorpheniramine is calculated by the probit methond. |
| In vitro | Oral administration of Chlorpheniramine (10 mg/kg) can suppress short-term scratching in BALB/c mice experiencing albumin-induced allergic skin irritation and ICR mice injected with histamine subcutaneously. Furthermore, in guinea pigs induced with histamine (ED50=0.17 mg/kg), oral intake of Chlorpheniramine prevents mortality. In rats, a dosage of Chlorpheniramine (20 mg/kg) is capable of blocking the histamine or cholinergic mechanisms that induce rapid eye movement (REM) sleep. |
| In vivo | Chlorpheniramine inhibits the binding of [3H] mepyramine to guinea pig cortical histamine H1 receptors (IC50=8.8 nM). It reduces ornithine decarboxylase mRNA translation in MCF-7, MDA-MB 231, and Ehrlich cells at a concentration of 250 μM, subsequently inhibiting cell proliferation. Chlorpheniramine displays antimalarial activity against Chloroquine-Sensitive (CQS) Plasmodium falciparum strain D6 (IC50=61.2uM) and Multidrug-Resistant (MDR) strain Dd2 (IC50=3.9uM). Furthermore, it exhibits cytotoxicity in mouse splenic lymphocytes induced by Concanavalin A (IC50=33.4 μM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (10.23 mM), Sonication is recommended.
H2O : 50 mg/mL (127.92 mM), Sonication is recommended.
DMSO : 100 mg/mL (255.84 mM), Sonication is recommended.
|
| Keywords | NCI-C-55265 | NCI-C 55265 | Inhibitor | inhibit | HistamineReceptor | Histamine Receptor | H1 receptor | Chlorpheniramine maleate | Chlorpheniramine | Chlorphenamine Maleate | Chlorphenamine |
| Inhibitors Related | Undecane | Betahistine mesylate | Histamine dihydrochloride | Meclizine dihydrochloride | Lidocaine | Famotidine | Sodium butanoate | Nizatidine | Alginic acid | Mianserin hydrochloride | Trazodone hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bitter Compound library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
